Kringle Pharma,Inc. Logo

Kringle Pharma,Inc.

Develops HGF-based regenerative medicines for rare and intractable diseases.

4884 | T

Overview

Corporate Details

ISIN(s):
JP3270790003
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号彩都バイオインキュベータ207号

Description

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-08-12 08:41
確認書
Japanese 9.1 KB
2022-08-12 08:41
四半期報告書-第21期第3四半期(令和4年4月1日-令和4年6月30日)
Japanese 180.4 KB
2022-05-13 08:40
四半期報告書-第21期第2四半期(令和4年1月1日-令和4年3月31日)
Japanese 217.3 KB
2022-02-14 07:00
四半期報告書-第21期第1四半期(令和3年10月1日-令和3年12月31日)
Japanese 194.1 KB
2021-12-27 02:20
確認書
Japanese 9.0 KB
2021-12-27 02:15
内部統制報告書-第20期(令和2年10月1日-令和3年9月30日)
Japanese 22.8 KB
2021-12-27 02:10
有価証券報告書-第20期(令和2年10月1日-令和3年9月30日)
Japanese 2.1 MB
2021-10-15 09:06
有価証券届出書(通常方式)
Japanese 2.4 MB
2021-08-13 09:09
四半期報告書-第20期第3四半期(令和3年4月1日-令和3年6月30日)
Japanese 153.6 KB
2021-05-14 09:00
四半期報告書-第20期第2四半期(令和3年1月1日-令和3年3月31日)
Japanese 166.9 KB
2021-02-12 07:20
四半期報告書-第20期第1四半期(令和2年10月1日-令和2年12月31日)
Japanese 134.8 KB
2020-12-28 07:07
確認書
Japanese 9.1 KB
2020-12-28 06:42
有価証券報告書-第19期(令和1年10月1日-令和2年9月30日)
Japanese 2.1 MB
2020-12-17 07:00
訂正有価証券届出書(新規公開時)
Japanese 2.0 MB
2020-12-09 01:01
訂正有価証券届出書(新規公開時)
Japanese 2.1 MB

Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kringle Pharma,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.